1-4 of 4
Ross Lindsay, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)

Andrew A. Lane, MD PhD, Kendra L. Sweet, MD, Eunice S. Wang, MD, William Donnellan, Roland B. Walter, MD PhD, Ioannis Mantzaris, MD, Michael B. Maris, MD, Dale L. Bixby, David A. Rizzieri, MD, Stefan Faderl, Madlen Malinowski, Naveen Pemmaraju, MD, Halyna Wysowskyj, Shay Shemesh, Janice Chen, PhD, Ross Lindsay, PhD, Christopher Brooks, PhD, Trishna Goswami, MD, Richard M. Stone, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2583.
https://doi.org/10.1182/blood.V130.Suppl_1.2583.2583
Published: 2017
Journal Articles

Resistance to SL-401 in AML and BPDCN Is Associated with Loss of the Diphthamide Synthesis Pathway Enzyme DPH1 and Is Reversible By Azacitidine

Jason Stephansky, Katsuhiro Togami, MDPhD, Mahmoud Ghandi, PhD, Joan Montero, PhD, Nick vonEgypt, Ross Lindsay, PhD, Christopher Brooks, PhD, Jon C. Aster, MD PhD, Cory Johannessen, PhD, Andrew A. Lane, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 797.
https://doi.org/10.1182/blood.V130.Suppl_1.797.797
Published: 2017
Journal Articles

Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)

Andrew A. Lane, MD PhD, Kendra L. Sweet, MD, Eunice S. Wang, MD, William B. Donnellan, MD, Roland B. Walter, MD PhD, Anthony S. Stein, MD, David A Rizzieri, MD, Hetty E. Carraway, MD MBA, Ioannis Mantzaris, MD, Thomas Prebet, MD PhD, Michael B. Maris, MD, Stefan Faderl, MD, Dale L. Bixby, MD PhD, Janice Chen, PhD, Ross Lindsay, PhD, Shay Shemesh, MA, Christopher L. Brooks, PhD, Richard M. Stone, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2016) 128 (22): 215.
https://doi.org/10.1182/blood.V128.22.215.215
Published: 2016
Journal Articles

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), and SL-801, a Reversible Inhibitor of Exportin-1 (XPO1), Display Synergistic Anti-Tumor Activity Against Hematologic Malignancies in Vitro

John Gionco, Janice Chen, PhD, Ross Lindsay, PhD, Vince Macri, M.A., Christopher L. Brooks, PhD
Journal: Blood
Blood (2016) 128 (22): 4724.
https://doi.org/10.1182/blood.V128.22.4724.4724
Published: 2016